2. Anavex Life Sciences Corp.
Disclaimer
The Presentation has been prepared by Anavex Life Sciences Corp. using its best efforts to realistically and factually
present the information contained. However, subjective opinion, dependence upon factors outside Anavex Life Sciences
Corp.’s control and outside information sources unavoidably dictate that Anavex Life Sciences Corp. cannot warrant the
information contained to be exhaustive, complete or sufficient. In addition, many factors can affect us which could
significantly alter the results intended by Anavex Life Sciences Corp., rendering the information/ projections in the
Presentation unattainable or substantially altered. Therefore, interested Users should conduct their own assessment and
consult with their own professional advisors prior to making any investment decisions.
This Presentation does not constitute a prospectus or public offering for financing, and no guarantees are made or implied
with regard to the success of Anavex Life Sciences Corp.’s proposed ventures. The Presentation is being disclosed to User
for User’s discussion, review, and/or evaluation only. User also agrees not to trade in the securities of Anavex Life Sciences
Corp. while in possession of any material information about Anavex Life Sciences Corp. that has not been publicly
disclosed.
User agrees to hold the Presentation, and all related information and discussions, in strict confidence, except that User may
disclose the Presentation to a limited number of advisors and employees of the User to the extent necessary for User to
adequately evaluate the Presentation. User warrants that any such employee shall be advised of the confidential nature of
the Presentation before gaining access to the same and that no such advisor or employee shall use or disclose the
Presentation except as specifically permitted by this Disclaimer.
User agrees that Anavex Life Sciences Corp. reserves all rights in and to the Presentation. User agrees to return all originals
and all copies of all materials related to Presentation to Anavex Life Sciences Corp. upon request or upon the conclusion of
User’s review and evaluation of the Presentation thereof, whichever is earlier.
Slide: 2
3. Anavex History Summary
σ Current pipeline of products developed over seven-years via research collaborations involving
Alexandre Vamvakides, PhD and other worldwide leaders in Sigma Receptors
σ Focus on treatments for Alzheimer’s Disease and Cancer
σ Reverse merger into OTCBB company January 2007
Slide: 3
4. Biopharmaceutical Industry Summary
σ The global pharmaceutical market grew to US $ 712 billion in 2007 at a compound annual growth rate
(CAGR) of 10.0% between 1999 and 2007.
σ The leading therapy area by sales was the Central Nervous System (CNS) with 16.5% share.
σ According to URCH Publishing, the global pharmaceutical market is forecasted to grow to $ 929 billion in
2012, an equivalent compound annual growth rate (CAGR) of 5.5% over the next 5-years.
σ In addition to the revenues’ rapid growth, drug companies have enjoyed extremely high returns on
investment capital in recent years as well as a favourable company survivorship rate compared with many
other industries.
σ According to IMS (Global healthcare advisor), annual sales for drugs that combat Alzheimer’s disease are
projected to reach US$8 billion by 2012.
Four of the seven Product Candidates Anavex have developed address diseases of the
CNS with its lead candidate an Alzheimer's compound
Anavex 2-73 soon to go into Human Clinical Trials
Slide: 4
5. Company Highlights
σ Anavex Life Sciences Corp. (www.anavex.com) is an emerging Biopharmaceutical Company. It is a
global Company with headquarters in Geneva, Switzerland. It is engaged in the discovery and
development of novel drugs which target the treatment of Cancer and Neurological Diseases of the
Central Nervous System (CNS), such as Alzheimer's, Epilepsy and Depression.
σ Anavex have a Scientific Advisory Board of world-renowned experts, a highly skilled Management
Team and an International Board of Directors.
σ Anavex has 7 product candidates in development for 8 disease indications. One of the products is
in IND stage and six of them in Preclinical stage. The Company’s target is to launch Human Clinical
Trials for 4 of its compounds (Alzheimer’s, Melanoma, Prostate and Epilepsy) by the beginning of
2010, while the other compounds will follow up.
σ When comparing data with the world’s leading Alzheimer’s drug Donepezil (Eisai/Pfizer), Donepezil
was active at a dose of 0.5mg/kg at least, Anavex 2-73 was fully active at 0.3 mg/kg and sometimes
(for some aspects) even at 0.1 mg/kg. The lower dosage logically leads to lower toxicity indication.
This finding alone makes Anavex 2-73, a strong candidate for Human Clinical Trials for Alzheimer's
Disease.
σ The Company has International Patents on all of its Product Candidates and has 35 new compounds
in the early Pre-clinical stage of development. International Patents will be obtained for these as
well as updates to Patents for existing product candidates.
σ Potential sales of the Company’s products after launch are estimated at US$6 billion.
Slide: 5
6. Sigmaceptor Platform: Anavex Product Candidates
ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drugs that target
NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, such as Alzheimer's disease, epilepsy,
depression, pain and neuropathic pain. The company's lead candidates have shown strong evidence for
anti-amnesic and neuroprotective properties in studies conducted to date. ANAVEX believes that
mitochondrial dysfunction can be modulated via SIGMA RECEPTORS, a unique class of receptor
molecules, to guard against oxidative stress.
ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel drugs targeting
CANCER. The company's lead candidates have shown strong evidence for selective pro-apoptotic,
anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has
already demonstrated its ability to significantly delay the growth of cancerous tumours in patient-derived
xenografts during advanced pre-clinical studies.
Seven Anavex Product Candidates
ANAVEX 3-97 MELANOMA
ANAVEX 7-1037 PROSTATE
ANAVEX 22-1068 PANCREAS
ANAVEX 2-73 ALZHEIMERS / DIABETES
ANAVEX19-144 EPILEPSY
ANAVEX 1-41 ALZHEIMERS / DEPRESSION
ANAVEX 10-90 NEUROPATHIC PAIN
Slide: 6
7. ANAVEX CURRENT PIPELINE PORTFOLIO PROSPECTS
Development Timeline and Costs 2009 - 2013
COMPUND YEAR
2009 2010 2011 2012 2013
ANAVEX 3-97 Cancer (Indic. Melanoma) Pre-clinical Phase II Phase II / III Phase III Phase III
ANAVEX 7-1037 Cancer (Indic. Prostate) Pre-clinical Phase I Phase I / II Phase II / III Phase III
ANAVEX 22-1068 Cancer (Indic. Pancreas) Pre-clinical Phase I Phase I / II Phase II / III Phase III
ANAVEX 2-73 Alzheimer’s IND Phase I Phase II Phase II / III Phase III
ANAVEX 2-73 Diabetic Degenerations Pre-clinical Pre-Clinical Pre-clinical IND / Phase I / II Phase II
ANAVEX 19-144 Epilepsy Pre-clinical IND / Phase 1 Phase I Phase II Phase II / III
ANAVEX 1-41 Alzheimer’s Pre-clinical IND Phase I Phase II Phase II / III
ANAVEX 1-41 Depression Pre-clinical IND Phase I Phase II Phase II
ANAVEX 10-90 Pain Pre-clinical Preclinical Pre-clinical IND / Phase I / II Phase II
Anavex’s Total Estimated Annual R&D Costs (in US$ million)
Year
Total R&D Costs 2009 2010 2011 2012 2013 Total
2.8 8.8 24.5 44 62.5 142.6
Slide: 7
8. Funding Requirements and Use Of Proceeds Breakdown To
September 2010
Anavex Requires USD$ 10.0 mil
to move four of its product
candidates into Phase I and one
of its candidates into Phase II of
development by September
2010. Of the USD$10.0 mil, 2.0
mil will be used for listing on the
AMEX stock exchange and for
general administration and
development costs.
The Company’s target is to
launch Human Clinical Trials for
four of its compounds
(Alzheimer's Disease, Melanoma,
Prostate Cancer and Epilepsy) by
the beginning of 2010 while other
compounds will follow.
9. Business Objectives over 24-Months Sep. 2009-2011
SEPTEMBER 2009 SEPTEMBER 2010 SEPTEMBER 2011
PRE-IND in Phase I in ALZHEIMER Phase II in ALZHEIMER
ALZHEIMER
Phase II in CANCER Phase II / III in CANCER
PRE-IND in CANCER (Melanoma) and (Melanoma) and Phase I in
and EPILEPSY IND / Phase I EPILEPSY EPILEPSY
No PARTNERSHIP 1 PARTNERSHIP in
ALZHEIMER and 2
1 PARTNERSHIP (outside
PARTNERSHIPS outside
Alzheimer)
ALZHEIMER
OTCBB Listing AMEX Listing NASDAQ Listing
(current)
11. Alzheimer’s Disease
σ Currently 28 million patients worldwide, with another person afflicted every minute
σ By 2050 1 in 85 persons worldwide will be living with the disease
σ Four currently marketed meds all off patent within five-years
1. Aricept (donepezil hydrochloride) Eisai and co-marketed with Pfizer
2. Exelon (rivastigmine) Novartis Pharmaceuticals
3. Reminyl (galantamine) Co-developed by Shire Pharmaceuticals
and the Janssen Research Foundation
4. Ebixa (memantine) Merz and marketed in Europe by Lundbeck
σ Alzheimer’s Disease is a ‘must-invest’ area for Big-Pharma
σ Only three early-stage, pure-play candidates available for Big-Pharma licensing
σ Competitive environment remarkably favorable for ANAVEX
σ Most other programs target mechanisms of action recently invalidated like anti-amyloid
Slide: 11
12. Co-development Deals In Alzheimer’s Disease Are Large
Anavex In Talks To Reach That Goal
Mode of
Company name Symbol Financing JV Status Action Phase date
Vitae Pharmaceuticals Private Upfront $ 42m Boehringer Beta-secretase Pre-clinical 15/06/2009
Milestones $ 242m Ingelheim inhibitors
Medivation MDVN Upfront $ 225m Pfizer Dimebon, II/III 03/09/2008
Milestones $ 725m mitochondrial effect
Co-Mentis Private Upfront $ 100m Astellas Beta-secretase I 25/04/2008
(formerly Athenagen) Milestones $ 760m inhibitors and +
nicotinic receptor discovery
agonists
Neurimmune Private $ 380m Biogen Idec Antibodies R&D 20/11/2007
Therapeutics
EPIX Pharmaceuticals EPIX Upfront $ 35m GlaxoSK plc 5 HTA partial Discovery 12/12/2006
Milestones $ 1200m agonist program
Idera Pharmaceuticals IDP Upfront 30m Merck & Co Toll-like receptor I 11/12/2006
Milestones $ 366m agonists
AC Immune Private $ 300m Genentech Anti beta amyloid preclinical 06/12/2006
antibodies
13. A Competitor’s Historical Share Price Chart
Medivation (MDVN: NASDAQ) is in Phase III Clinical Trials with its Alzheimer’s Drug,
Dimebon (JV with Pfizer). The Chart below shows the spike in 2008 when it was still in
Phase II, before the worldwide market crash. It traded at an all-time high of USD$ 33.80
on September 5th, 2008. Recovery from the crash has been steady with the Company
closing at USD$27.63 October 8th.
Slide: 13
14. Anavex’s Rich Oncology Pipeline
σ Oncology (cancer) is a fast growing US$ 8bn market
σ ANAVEX should have 3 compounds in the clinics and ready to
partner in 18 months
σ One compound could advance directly into Phase II
σ ANAVEX will become an active target for Big Pharma:
• Phase I or II data with novel compounds
• Platform for further productivity in a new mechanism of action
Slide: 14
15. Oncology Companies Comparable to Anavex in 12 - 18 months
Achieve High Market Caps Even Without Alzheimer’s Compound
Therapeutic
Company Name Stage Market Cap
Area
Anavex Pre-IND $ 52m Oncology, CNS,
Alzheimer’s Disease
Alnylam Phase II $ 928m Oncology, others
Ardea Phase II $ 295m Oncology, Gout,
HIV
Arqule Phase II $ 280m Oncology
Array Phase II $ 175m Oncology,
inflammation,
metabolism
Celldex Phase II $ 124m Oncology, infectious
disease
Dendreon Phase II-III $ 2.4bn Oncology
* as at October 15, 2008
with data from Wm. Lowry Research and Yahoo Finance
16. Recent Acquisitions Of Oncology (Cancer) Products
Anavex In Talks To Sign Similar Type Of Deal
Therapeutic
Company Name Product Acquirer Date Stage Upfront Milestones
Area
BiPar Sciences Sanofi-aventis 15/04/2009 Phase II $ 500m Oncology
Incorporated
Arana Cephalon, Inc. 27/02/2009 Phase II & $ 207m Oncology and
Therapeutics preclinical inflammatory
Limited
Arius Research Roche 23/07/2008 Preclinical, $ 189m Oncology and
immunology
SGX Eli Lilly and Co 08/07/2008 Phase I & $ 64m Oncology
Pharmaceuticals, Preclinica
Inc.
U3 Pharma AG Daiichi Sankyo 21/05/2008 Preclinical & $ 235m Oncology
Co., Ltd. Research
Piramed Pharma Roche 15/04/2008 Phase Ib $ 160m $ 175m Oncology and
plus inflammatory
preclinical
Agensys, Inc. Astellas 27/11/2007 Phase Ib $ 387m $ 537m Oncology
plus
preclinical
Adnexus Bristol-Myers 24/08/2007 Phase I $ 430m $ 505m Oncology
Therapeutics Squibb
Morphotek Eisai Inc. 22/03/2007 Phase I and $ 325m Oncology and
preclinical Inflammatory
and infectious
* as of October 15, 2008
with data from Wm. Lowry Research and Yahoo Finance
17. Key Management
Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director
• Dr. de Kergrohen has extensive experience in building and transforming organizations, with
more than 25 years in senior and executive management positions, including CEO, Chairman
or Director roles with more than 12 companies in the United States and Europe.
Alexandre Vamvakides, PhD, Scientific Founder, Chief Scientific Officer,
Chairman of Scientific Advisory Board
• More than 30 years in anti-neurodegenerative (anti-Alzheimer’s), anti-epileptic, anti-
depressive research and development
• Author of more than 80 published scientific papers
• Institut national de la santé et de la recherche médicale (INSERM), University of Athens,
Ciba-Geigy (now Novartis), sanofi-aventis
• Track record of discovery and development of novel concepts in central nervous system
(CNS), oncology and anti-inflammatory diseases
Harvey Lalach, President, CFO, Secretary and Director
• Various aspects of the securities industry for over 20 years
• Focused on the operation and administration of numerous start-up US and Canadian public
companies, serving in both director and officer capacities
• Extensive experience in the management and governance of listed public companies
Slide: 17
18. International Board
Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director
• Dr. de Kergrohen has extensive experience in building and transforming organizations, with more than 25 years in senior and
executive management positions, including CEO, chairman or director roles with more than 12 companies in the United States and
Europe.
• Life Science Investment Advisor and Board Member/ High-level Consultant at Kergrohen & Associates.
• Venture Partner at with CDC Innovation, an international venture capital firm with over 415-million Euros under its management.
• Founder of BioData, a biotech conference held annually in Geneva.
Cameron Durrant, MD, MBA, Chairman of the Board
• Merck, GSK, Pharmacia, J&J (Worldwide Vice President, Global Strategic Marketing)
• Former CEO, PediaMed; former CEO, Spherics
• 2005 Ernst & Young healthcare ‘Entrepreneur of the Year’
• Co-founding Board member privately held oncology company (Bexion)
Alison Ayers, MSc, Director
• Worldwide Commercial Head for Oncology, Pfizer
• More than 20 years of oncology-focused pharmaceutical industry experience
• Business and product planning: Pharmacia, Merck, US Bioscience, BMS, Lederle Laboratories
David L. Tousley, CPA, MBA, Director
• President, COO and CFO at companies including airPharma, PediaMed Pharmaceuticals, AVAX Technologies and Pasteur, Merieux,
Connaught (now sanofi-aventis)
• Over $90MM in debt and equity financings
• Leadership of key business development activities, including joint ventures, partnerships, acquisitions and divestitures in the US,
Europe and Australia
Harvey Lalach, President, CFO, Secretary and Director
• Various aspects of the securities industry for over 20 years
• Focused on the operation and administration of numerous start-up US and Canadian public companies, serving in both director and
officer capacities
• Extensive experience in the management and governance of listed public companies
Slide: 18
19. Scientific Advisory Board Of World-Renowned Experts
Alexandre Vamvakides, PhD
• Chairman of Scientific Advisory Board, also company’s Scientific Founder and Chief Scientific Officer
Jean-Jacques Bourguignon, PhD
• 30 years experience in medicinal chemistry, including expertise in drug design and optimization as well as organic
and physical chemistry
• Research Director (CNRS) at the Faculty of Pharmacy, Strasbourg-Illkrich, France
Tangui Maurice, PhD
• 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors,
neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related
disorders, and behavioral phenotyping of rodent models
• Former behavioral neuropharmacologist, INSERM U710, Montpellier
Mark Smith, Ph.D., FRCPath
• A leading researcher and professor in the Department of Pathology at Case Western Reserve University School of
Medicine, and one of the world’s most cited researchers in the fields of Alzheimer’s disease, free radical biology and
neuroscience and behavior
• Executive Director of the American Aging Association and Editor-in-Chief of the Journal of Alzheimer’s Disease
having authored over 600 peer-reviewed scientific manuscripts and book chapters
• Scientific research, currently focused on investigating the pathological mechanisms underlying selective neuronal
death in neurodegenerative diseases, notably Alzheimer’s disease
Slide: 19
20. Stock Summary – As At August 14th, 2009
Stock Symbol AVXL.OB
Shares Outstanding 20,746,761
Warrants Outstanding 986,147
Options Outstanding 3,075,000
Shares Fully Diluted 24,807,908
Market Capitalization $52.48MM
% Held by Insiders 50%
% Float 50%
Funding History Summary
• Research grants, self-financed by CSO (1998-2004)
• $7.0MM pre-public by founding shareholder and affiliates (2004-2007)
• $2.5MM equity and converted debt over $3.50/share (2007)
• $1.6MM debt / $0.8MM equity (2008)
• $818,000 debt / $2,254,143 equity (2009)
Slide: 20
21. Anavex’s Three-Year Historical Trading Chart
2007-2009
Anavex (AVXL:OB) will move up to the AMEX exchange in Q1, 2010
as it enters into Human Clinical Trials for its Alzheimer's Compound
Anavex 2-73.
Slide: 21
